Global chronic obstructive pulmonary disease treatment market income is anticipated to value around USD 24.3 billion by the end of 2026. The market is anticipated to develop with a CAGR of 4.9% between the years 2018 to 2026.
The market is driven by Increase in the numeral of COPD cases, increase in FDA approval, and continuous launch of a few products in the U.S. In addition, increment in the geriatric populace and rise in use on pharmaceuticals in rising nations are alternate components adding to the development of the market. Nonetheless, patent expiry of marked products and accessibility of conventional counterparts and elective treatment alternatives are foreseen to control the worldwide market.
High occurrence of COPD, promising medications in pipeline, development of the pharmaceutical business in developing markets, for example, Asia Pacific, and launch of products, for example, inhalers are anticipated to increase the worldwide market from the year 2018 to 2026.
Increase in commonness of COPD, high environmental contamination, increment in the geriatric populace, and development of the pharmaceutical business are foreseen to fuel the development of the chronic obstructive pulmonary disease (COPD) treatment market in Asia Pacific. An article published in the International Journal of Pulmonary and Respiratory Sciences expressed that COPD is the third driving reason for death in India.
On the basis of drug class, the worldwide chronic obstructive pulmonary disease treatment market has been sectioned into bronchodilators, combination, phosphodiesterase type 4 inhibitors, corticosteroids, mucokinetics, and others. The combination segment has been segmented into long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), and others. The bronchodilators segment has been bifurcated into short acting beta agonist (SABA), long acting beta agonist (LABA), and long acting muscarinic rival (LAMA). The combination segment is anticipated to represent major share of the market by 2026 because of increment in number of doctors recommending combination treatment and increase in the number of medications accessible for COPD treatment. The bronchodilators segment is foreseen to develop at a steady pace attributable to increment in the appropriation of long acting muscarinic rival (LAMA) drugs.
Market By Drug Class
Market By Distribution Channel
Market By Geography
Based on the region, the worldwide chronic obstructive pulmonary disease (COPD) treatment market has been classified into Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. North America represented the biggest revenue share of the worldwide market in 2018. Presence of built up pharmaceutical organizations, increment in adoption of new drugs propelled in the market, and concentrate on dispatch of new products through R&D are foreseen to drive the market in the area amid the estimate time frame.
The chronic obstructive pulmonary disease (COPD) treatment industry in Europe is driven by increment in R&D spending and introduction of new products. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. gotten approval from the European Commission for extended use for once-daily TrelegyEllipta, first single inhaler triple treatment demonstrated for COPD patients who were not enough treated with dual bronchodilation.
Main enterprises working in the global chronic obstructive pulmonary disease treatment market are Orion Corporation, AstraZeneca, Mylan N.V., BoehringerIngelheim Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc. and CHIESI Farmaceutici S.p.A.
Healthcare drones provide medical care facilities for the people in a few minutes to bring blood, medicines, serum snake bite, birth control, and other resources to rural areas, which in some situations could be the difference between life and death. Market Insights Increased awareness of healthcare drones is likely to fuel dema
The Global Metal Implants and Medical Alloys Market size is expected to garner around US$ 19.5 Bn by 2026, growing at a CAGR of around 9.2% over the forecast period 2019 to 2026. Metal implants are the biomaterials that are used to place inside or on the surface of the body. These are basically made up of stainless steel, Cobalt Chrome (CoCr) alloys, Titanium (Ti), and Ti alloys are widely used in orthopedic i
The Global Next Generation Sequencing Market is expected to grow at a CAGR of around 18.7% over the forecast period 2019 to 2026 and poised to reach around US$ 20.4 Bn by 2026. Next Generation Sequencing (NGS) is a platform that enabled the sequencing of thousands to millions DNA molecules simultaneously. It is also known as the massively parallel sequencing technology. This sequencing helps in the various fie
The global ultrasound equipment market is expected to grow at a CAGR of around 6.3% from 2019 to 2026 and expected to reach the market value of around US$ 10 Bn by 2026. Ultrasound is a medical imaging technology that uses sound waves to produce pictures of body’s inside part. It helps to diagnose swelling, pain, and infection in internal organs and to examine a baby in pregnant women. Ultrasound is also
The global minimally invasive surgery market is expected to grow at a CAGR of around 9.6% over the forecast period 2019 to 2026 and expected to reach the market value of around US$ 33.8 Bn by 2026. Minimally invasive surgery uses techniques to operate with less incision or damage to the body than open surgery. Hence, it is associated with less pain, fewer postoperative complications, and short
The global implantable medical devices market is expected to grow at a CAGR of around 7.3% over the forecast period 2019 to 2026 and expected to reach the market value of around US$ 153.8 Bn by 2026. An implant is a medical device, manufactured to support or replace any damaged organs in the body, treat imperfections in normal body functions, or enhance the functioning of body organs. These can be implanted by